439 related articles for article (PubMed ID: 24285106)
1. Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1.
Del Prete M; Marotta V; Ramundo V; Marciello F; Di Sarno A; Esposito R; Carratù AC; De Luca Di Roseto C; Di Somma C; Colao A; Faggiano A
Minerva Endocrinol; 2013 Dec; 38(4):389-94. PubMed ID: 24285106
[TBL] [Abstract][Full Text] [Related]
2. MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly.
Filopanti M; Verga U; Ermetici F; Olgiati L; Eller-Vainicher C; Corbetta S; Persani L; Beck-Peccoz P; Spada A
Eur J Endocrinol; 2012 Aug; 167(2):157-64. PubMed ID: 22577108
[TBL] [Abstract][Full Text] [Related]
3. A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet.
Falchetti A; Cilotti A; Vaggelli L; Masi L; Amedei A; Cioppi F; Tonelli F; Brandi ML
Nat Clin Pract Endocrinol Metab; 2008 Jun; 4(6):351-7. PubMed ID: 18414463
[TBL] [Abstract][Full Text] [Related]
4. Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1).
Giusti F; Cianferotti L; Gronchi G; Cioppi F; Masi L; Faggiano A; Colao A; Ferolla P; Brandi ML
Endocrine; 2016 Jun; 52(3):495-506. PubMed ID: 26224587
[TBL] [Abstract][Full Text] [Related]
5. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.
Faggiano A; Tavares LB; Tauchmanova L; Milone F; Mansueto G; Ramundo V; De Caro ML; Lombardi G; De Rosa G; Colao A
Clin Endocrinol (Oxf); 2008 Nov; 69(5):756-62. PubMed ID: 18485119
[TBL] [Abstract][Full Text] [Related]
6. Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy.
Iglesias P; Ais G; González A; Tajada P; García Arévalo C; Fernández Pardo E; Díez JJ
Am J Med Sci; 2008 Feb; 335(2):111-4. PubMed ID: 18277118
[TBL] [Abstract][Full Text] [Related]
7. Cinacalcet for the treatment of primary hyperparathyroidism.
Dillon ML; Frazee LA
Am J Ther; 2011 Jul; 18(4):313-22. PubMed ID: 20228675
[TBL] [Abstract][Full Text] [Related]
8. Cinacalcet HCl suppresses Cyclin D1 oncogene-derived parathyroid cell proliferation in a murine model for primary hyperparathyroidism.
Imanishi Y; Kawata T; Kenko T; Wada M; Nagano N; Miki T; Arnold A; Inaba M
Calcif Tissue Int; 2011 Jul; 89(1):29-35. PubMed ID: 21541686
[TBL] [Abstract][Full Text] [Related]
9. [Low-dose cinacalcet reduces serum calcium in patients with primary hyperparathyroidism not eligible for surgery].
Arranz Martín A; Azcárate Villalón A; Luque Ramírez M; Santana Durán B; Marazuela Azpíroz M; Paniagua Ruiz A; Carraro R; Gómez Pan A
Endocrinol Nutr; 2011 Jan; 58(1):24-31. PubMed ID: 21277266
[TBL] [Abstract][Full Text] [Related]
10. Cinacalcet treatment for stable kidney transplantation patients with hypercalcemia due to persistent secondary hyperparathyroidism: a long-term follow-up.
Paschoalin RP; Torregrosa JV; Sánchez-Escuredo A; Barros X; Durán CE; Campistol JM
Transplant Proc; 2012 Nov; 44(9):2588-9. PubMed ID: 23146463
[TBL] [Abstract][Full Text] [Related]
11. Primary hyperparathyroidism in MEN1 patients: a cohort study with longterm follow-up on preferred surgical procedure and the relation with genotype.
Pieterman CR; van Hulsteijn LT; den Heijer M; van der Luijt RB; Bonenkamp JJ; Hermus AR; Borel Rinkes IH; Vriens MR; Valk GD;
Ann Surg; 2012 Jun; 255(6):1171-8. PubMed ID: 22470073
[TBL] [Abstract][Full Text] [Related]
12. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
Dong BJ
Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
[TBL] [Abstract][Full Text] [Related]
13. Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use.
Norman J; Lopez J; Politz D
Ann Surg Oncol; 2012 May; 19(5):1466-71. PubMed ID: 21922336
[TBL] [Abstract][Full Text] [Related]
14. Cinacalcet de novo in persistent hypercalcemia after kidney transplantation secondary to hyperparathyroidism: long-term follow-up and effect of withdrawal.
Paschoalin RP; Torregrosa JV; Barros X; Durán CE; Campistol JM
Transplant Proc; 2012 Oct; 44(8):2376-8. PubMed ID: 23026597
[TBL] [Abstract][Full Text] [Related]
15. Reoperative Surgery in Patients with Multiple Endocrine Neoplasia Type 1 Associated Primary Hyperparathyroidism.
Keutgen XM; Nilubol N; Agarwal S; Welch J; Cochran C; Marx SJ; Weinstein LS; Simonds WF; Kebebew E
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):701-707. PubMed ID: 27464610
[TBL] [Abstract][Full Text] [Related]
16. Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.
Khan A; Grey A; Shoback D
J Clin Endocrinol Metab; 2009 Feb; 94(2):373-81. PubMed ID: 19193912
[TBL] [Abstract][Full Text] [Related]
17. Bone and Mineral Metabolism Phenotypes in MEN1-Related and Sporadic Primary Hyperparathyroidism, before and after Parathyroidectomy.
Marini F; Giusti F; Cioppi F; Maraghelli D; Cavalli T; Tonelli F; Brandi ML
Cells; 2021 Jul; 10(8):. PubMed ID: 34440663
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
[TBL] [Abstract][Full Text] [Related]
19. Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group.
Saponaro F; Faggiano A; Grimaldi F; Borretta G; Brandi ML; Minisola S; Frasoldati A; Papini E; Scillitani A; Banti C; Del Prete M; Vescini F; Gianotti L; Cavalli L; Romagnoli E; Colao A; Cetani F; Marcocci C
Clin Endocrinol (Oxf); 2013 Jul; 79(1):20-6. PubMed ID: 23228121
[TBL] [Abstract][Full Text] [Related]
20. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism.
Kruse AE; Eisenberger U; Frey FJ; Mohaupt MG
Nephrol Dial Transplant; 2005 Jul; 20(7):1311-4. PubMed ID: 15941846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
